Eli Lilly’s EloraTZP combo shows up to 23.3% weight loss and 2.9% HbA1c drop in phase 2b study
Eli Lilly reported that its investigational combination of eloralintide and tirzepatide (EloraTZP) produced a maximum 23.3% reduction in body weight and a 2.9% decrease in HbA1c after 48 weeks in adults with obesity or overweight and type 2 diabetes. The double‑blind, placebo‑controlled study enrolled 367 participants in the United States and Argentina and compared four dose combinations of EloraTZP with tirzepatide alone, eloralintide alone and placebo. Gastro‑intestinal side effects were the most common adverse events, and discontinuations due to safety ranged between 10.8% and 27.0% in the combination arms. Lilly plans to start phase 3 trials of a co‑formulation by the end of 2026.
Why it matters
The company says the strong efficacy could broaden its cardiometabolic pipeline and offer a new option for patients who need greater weight and glucose control; investors may see future revenue growth if the product reaches market. The trial’s safety profile indicates higher discontinuation rates than tirzepatide alone, which could affect adoption and pricing.
Key facts
- 1The trial enrolled 367 adults with obesity or overweight and type 2 diabetes. hcplive.com
- 2Mean baseline body weight was 105.4 kg and mean baseline HbA1c was 8.1%. hcplive.com
- 3The highest EloraTZP dose (eloralintide 9 mg + tirzepatide 15 mg) reduced weight by 23.3% and HbA1c by 2.9% at 48 weeks. hcplive.com
- 4Tirzepatide 15 mg alone produced 14.8% weight loss and a 2.4% HbA1c reduction. hcplive.com
- 5Discontinuations due to adverse events were between 10.8% and 27.0% in the EloraTZP groups, versus 0%–10.8% with eloralintide alone, 2.9% with tirzepatide alone and 16.7% with placebo. hcplive.com
- 6Lilly intends to begin phase 3 trials of an EloraTZP co‑formulation by the end of 2026. hcplive.com
Summary written by AlphAI from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.